Gsk Dividends - GSK

Gsk Dividends - GSK

Buy
Sell
Best deals to access real time data!
Silver
Monthly Subscription
for only
£17.37
Level 2 Basic
Monthly Subscription
for only
£62.08
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type
Gsk Plc GSK London Ordinary Share
  Price Change Price Change % Stock Price Last Trade
13.80 0.77% 1,799.40 16:05:03
Open Price Low Price High Price Close Price Previous Close
1,792.20 1,789.80 1,812.40 1,785.60
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Gsk GSK Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
27/04/20221GBX1431/12/202131/12/202219/05/202220/05/202201/07/20220
09/02/2022FinalGBX2331/12/202031/12/202124/02/202225/02/202207/04/202280
27/10/20211GBX1931/12/202031/12/202118/11/202119/11/202113/01/20220
28/07/20211GBX1931/12/202031/12/202119/08/202120/08/202107/10/20210
28/04/20211GBX1931/12/202031/12/202120/05/202121/05/202108/07/20210
03/02/2021FinalGBX2331/12/201931/12/202018/02/202119/02/202108/04/202180
28/10/20201GBX1931/12/201931/12/202012/11/202013/11/202014/01/20210
29/07/20201GBX1931/12/201931/12/202013/08/202014/08/202008/10/20200
29/04/20201GBX1931/12/201931/12/202014/05/202015/05/202009/07/20200
05/02/2020FinalGBX2331/12/201831/12/201920/02/202021/02/202009/04/202080
30/10/20191GBX1931/12/201831/12/201914/11/201915/11/201909/01/20200
24/07/20191GBX1931/12/201831/12/201908/08/201909/08/201910/10/20190
01/05/20191GBX1931/12/201831/12/201916/05/201917/05/201911/07/20190
06/02/2019FinalGBX2331/12/201731/12/201821/02/201922/02/201911/04/201980
31/10/20181GBX1931/12/201731/12/201815/11/201816/11/201810/01/20190
25/07/20181GBX1931/12/201731/12/201809/08/201810/08/201811/10/20180
25/04/20181GBX1931/12/201731/12/201810/05/201811/05/201812/07/20180
07/02/2018FinalGBX2331/12/201631/12/201722/02/201823/02/201812/04/201880
25/10/20171GBX1931/12/201631/12/201709/11/201710/11/201711/01/20180
26/07/20171GBX1931/12/201631/12/201710/08/201711/08/201712/10/20170
26/04/20171GBX1931/12/201631/12/201711/05/201712/05/201713/07/20170
08/02/2017FinalGBX2331/12/201531/12/201623/02/201724/02/201713/04/201780
26/10/20161GBX1931/12/201531/12/201603/11/201604/11/201612/01/20170
27/07/20161GBX1931/12/201531/12/201611/08/201612/08/201613/10/20160
27/04/20161GBX1931/12/201531/12/201612/05/201613/05/201614/07/20160
03/02/2016SpecialGBX2031/12/201431/12/201518/02/201619/02/201614/04/20160
03/02/2016FinalGBX2331/12/201431/12/201518/02/201619/02/201614/04/2016100
19/10/20151GBX1931/12/201431/12/201512/11/201513/11/201514/01/20160
29/07/20151GBX1931/12/201431/12/201513/08/201514/08/201501/10/20150
06/05/20151GBX1931/12/201431/12/201514/05/201515/05/201509/07/20150
04/02/2015FinalGBX2331/12/201331/12/201419/02/201520/02/201509/04/201580
22/10/20141GBX1931/12/201331/12/201406/11/201407/11/201408/01/20150
24/07/20141GBX1931/12/201331/12/201406/08/201408/08/201402/10/20140
30/04/20141GBX1931/12/201331/12/201414/05/201416/05/201410/07/20140
05/02/2014FinalGBX2331/12/201231/12/201319/02/201421/02/201410/04/201478
23/10/20131GBX1931/12/201231/12/201313/11/201315/11/201309/01/20140
24/07/20131GBX1831/12/201231/12/201307/08/201309/08/201303/10/20130
24/04/20131GBX1831/12/201231/12/201308/05/201310/05/201311/07/20130
06/02/2013FinalGBX2231/12/201131/12/201220/02/201322/02/201311/04/201374
31/10/20121GBX1831/12/201131/12/201214/11/201216/11/201203/01/20130
25/07/20121GBX1731/12/201131/12/201208/08/201210/08/201204/10/20120
25/04/20121GBX1731/12/201131/12/201209/05/201211/05/201205/07/20120
07/02/2012SpecialGBX531/12/201031/12/201115/02/201217/02/201212/04/20120
07/02/2012FinalGBX2131/12/201031/12/201115/02/201217/02/201212/04/201275
26/10/2011InterimGBX1731/12/201031/12/201102/11/201104/11/201105/01/20120
26/07/2011InterimGBX1631/12/201031/12/201103/08/201105/08/201106/10/20110
27/04/2011InterimGBX1631/12/201031/12/201104/05/201106/05/201107/07/20110
03/02/2011FinalGBX1931/12/200931/12/201009/02/201111/02/201107/04/201165
21/10/2010InterimGBX1631/12/200931/12/201027/10/201029/10/201006/01/20110
21/07/2010InterimGBX1531/12/200931/12/201028/07/201030/07/201007/10/20100
28/04/2010InterimGBX1531/12/200931/12/201005/05/201007/05/201008/07/20100
04/02/2010FinalGBX1831/12/200831/12/200910/02/201012/02/201008/04/201061
29/10/20091GBX1531/12/200831/12/200904/11/200906/09/200907/01/20100
30/07/20091GBX1431/12/200831/12/200931/07/200931/07/200908/10/200928
22/04/20091GBX1431/12/200831/12/200929/04/200901/05/200909/07/20090
05/02/2009FinalGBX1731/12/200731/12/200811/02/200913/02/200909/04/200957
22/10/20081GBX1431/12/200731/12/200829/10/200831/10/200809/01/20080
07/02/2008FinalGBX1331/12/200631/12/200713/02/200815/02/200810/04/200853
25/07/20071GBX1231/12/200631/12/200701/08/200703/08/200711/10/20070
24/04/20071GBX1231/12/200631/12/200702/05/200704/05/200712/07/20070
08/02/2007FinalGBX031/12/200531/12/200601/01/197001/01/197001/01/197048
08/02/20071GBX1431/12/200531/12/200614/02/200616/02/200612/04/20070
26/10/20061GBX1231/12/200531/12/200601/11/200603/11/200604/01/20070
26/07/20061GBX1131/12/200531/12/200602/08/200604/08/200605/10/20060
27/04/20061GBX1131/12/200531/12/200610/05/200612/05/200606/07/20060
08/02/2006FinalGBX1431/12/200431/12/200515/02/200617/02/200606/04/200644
27/10/20051GBX1031/12/200431/12/200502/11/200504/11/200505/01/20060
29/07/20051GBX1031/12/200431/12/200503/08/200505/08/200506/10/20050
28/04/20051GBX1031/12/200431/12/200511/05/200513/05/200507/07/20050
10/02/2005FinalGBX1231/12/200331/12/200416/02/200518/02/200507/04/200542
28/10/20041GBX1031/12/200331/12/200403/11/200405/11/200406/01/20050
27/07/20041GBX1031/12/200331/12/200412/05/200414/05/200401/07/20040
27/07/20041GBX1031/12/200331/12/200404/08/200406/08/200430/09/20040
12/02/2004FinalGBX1431/12/200231/12/200318/02/200420/02/200415/04/200441
11/02/20041GBX931/12/200231/12/200329/10/200331/10/200306/01/20040
23/07/20031GBX931/12/200231/12/200330/07/200301/08/200302/10/20030
30/04/20031GBX931/12/200231/12/200307/05/200309/05/200303/07/20030
12/02/2003FinalGBX1331/12/200131/12/200219/02/200321/02/200317/04/200340
23/10/20021GBX930/03/200230/09/200230/10/200201/11/200203/01/20030
24/07/20021GBX930/12/200130/06/200231/07/200202/08/200203/10/20020
25/04/20021GBX901/10/200131/03/200201/05/200203/05/200204/07/20020
14/02/2002FinalGBX1231/12/200031/12/200120/02/200222/02/200218/04/200239
23/10/20011GBX930/09/200030/09/200131/10/200102/11/200103/01/20020
24/07/20011GBX930/06/200030/06/200101/08/200103/08/200104/10/20010
24/04/20011GBX931/03/200031/03/200102/05/200104/05/200105/07/20010
13/12/2000FinalGBX2331/12/199931/12/200018/12/200022/12/200017/04/200138
27/07/2000InterimGBX1530/12/199930/06/200007/08/200011/08/200016/10/20000
16/02/2000FinalGBX2231/12/199831/12/199928/02/200003/03/200025/05/200037
29/07/1999InterimGBX1530/12/199830/06/199909/08/199913/08/199901/10/19990
18/02/1999FinalGBX2131/12/199731/12/199801/03/199905/03/199920/05/199936

Top Dividend Posts

DateSubject
03/7/2022
12:53
anhar: Here's the bit that concerns me: 14 July, scrip dividend, whereby GSK investors get HAL shares (1 for 1). But, they are only releasing 80% of GSK's 68% holding in Consumer Health. At the moment, I am unwilling to keep invested in a pig in a poke (something offered in such a way as to obscure its real nature or worth). I don't get that reluctance TM. The value of Haleon (or any share) depends upon the market's perception of a host of factors such as assets, P/E, the quality of the business, yield, possible bid potential etc. There's nothing hidden, any more than with any company. I don't see why then it's a "pig in a poke". The temporary retained shareholdings of GSK, or Pfizer come to that, don't make any difference to the company itself. Both have stated they intend to dispose of their holdings after the lock up period. As I've said despite the large divi cut from the two new shares over old GSK, I'm definitely going to retain my Haleon to see how it develops, especially its divis.
28/6/2022
12:02
mj19: What the brokers say Barclays Capital has trawled through 400-odd-page prospectus and distilled its findings into a far less chunky 23-page overview. Two things struck us from the note. The first, was the indicative valuation range, which, based on a price-to-earnings calculation used to assess companies in the consumer staples sector, comes up well short of the £50bn tentatively tabled by Unilever. Barclays reckons Haleon shares, once listed on July 18, could be worth anywhere from 249p to 416p, which adds up to an equity valuation of £23bn-£38bn. This is based on valuations ‘multiplesR17; ranging from 15 to 25 times earnings. The second interesting ‘takeaway̵7; from the note was the bank’s interaction with key shareholders on the issue organic sales growth – a major driver of the company’s valuation. In the note, Barclays said there was “a degree of scepticism” among investors as to whether Haleon could actually hit the 4%-7% top-line target it has set itself. Indeed, it went on to say there was “significant pushback on our 4.7% medium-term growth forecast”. Jefferies, the American bank that has a stellar reputation in the healthcare sector, has assessed the demerger from GSK’s investment perspective. It believes that by spinning out Haleon, whose stock trade is painkillers such as Advil, the UK pharma group has divested itself of a headache (its words not mine). It has based its ‘buy’ recommendation and £21 a share price target on GSK’s own medium-term growth forecasts – an average 6% increase in sales and 12%-14% compound annual growth in per share earnings. “New GSK is underappreciated, as the number-two growth profile in EU large-caps,” Jefferies said in its note. “We accept New GSK pipeline remains a work-in-progress, but catalysts are starting to emerge, and the vaccines franchise just keeps getting better.” One thing to ponder Those who hold GSK currently as income play (it yields 4.7% or thereabouts currently) will see a cut in the combined GSK/Haleon pay-out post-demerger. It is estimated that GSK will distribute around 44p a share in Haleon 11p, giving a 3.2% yield.
27/6/2022
06:27
garycook: From the GSK Circular to Shareholders Following Separation, the price of a GSK Share is expected to fall to reflect the demerger of the Haleon Business from the GSK Group. However, Shareholders will have received one Haleon Share for each GSK Share held at the Shareholder Record Time and their retained GSK Shares and their new Haleon Shares will together represent the GSK Shares held by them pre-Separation. The actual aggregate value of those GSK Shares and Haleon Shares will be dependent on their respective market prices post-Separation. In light of this expected fall in the price of a GSK Share, it is proposed that GSK will consolidate its existing share capital to reduce the number of GSK Shares in issue. The intention of the GSK Share Consolidation is to: • reduce the number of GSK Shares which will increase the price of a GSK Share so that there will be general comparability between GSK’s share price before and after the Separation (subject to any interim market movements). This should enable the GSK Group’s earnings per share and share price to be more readily compared to previous financial periods; and • preserve (as far as reasonably possible) the value of options and awards granted under the GSK Executive Schemes and GSK UK Sharesave, thereby avoiding the need for any specific adjustments to the numbers and/or exercise price of options and awards under those schemes
27/6/2022
05:51
garycook: What will happen to GSK shares when the company splits? Glaxo aims to complete the demerger and listing of its consumer healthcare business, Haleon, by July 18th. Investors will receive one share in Haleon for every existing Glaxo share they own, leaving the pharmaceutical company's investors owning 54.5% of the new business.With the current GSK share price at 1756.20p.Then whatever the Haleon share price is given.This will be deducted from the GSK share price ! eg If you own 1,000 GSK,you will receive 1,000 Haleon.Jonjoneil you are wrong Post 29896.But whatever the share price s of GSK,and Haleon are on July 18 should total around the GSK share price of July 15.eg July 18 around GSK £10,and Haleon 750p ish.Jonjoneil.How do you calculate a GSK share price of £19 ?
26/6/2022
14:56
zho: >>Looking like maybe around £10 for New GSK>> I don't get that. Glaxo are consolidating GSK shares for reasons of "consistency" - so that the share price after the split looks pretty much as it did before the split. Or at least, that's how I understand this paragraph: "Following completion of the Demerger and listing of Haleon, GSK intends to carry out the GSK Share Consolidation. This is intended to provide consistency in the GSK share price pre- and post-separation (subject to interim market movements), in order to enable comparability between the Company's earnings per share and share price with previous periods."
26/6/2022
07:28
grupo guitarlumber: Drugs giant GSK says encouraging results from trial of its hepatitis B treatment raises hopes for millions suffering from chronic infection By Neil Craven, Financial Mail on Sunday Published: 21:50 BST, 25 June 2022 | Updated: 23:17 BST, 25 June 2022 Drugs giant GSK said encouraging results from a trial of its hepatitis B treatment have raised hopes for millions suffering from chronic infection. It estimated its treatment bepirovirsen could generate peak annual sales of more than £2billion ($2.5billion) if later stage trials are successful. Boost: GSK estimated its treatment bepirovirsen could generate peak annual sales of more than £2billion ($2.5billion) if later stage trials are successful Boost: GSK estimated its treatment bepirovirsen could generate peak annual sales of more than £2billion ($2.5billion) if later stage trials are successful The development follows positive news earlier this month from a phase three trial in older adults for its RSV vaccine for respiratory disease. Shareholders including activist Elliott view the RSV vaccine, for which GSK will seek approval by the end of the year, as vital for the company's success and are likely to be cheered by the encouraging data on bepirovirsen. How to choose the best (and cheapest) stocks and shares Isa and the right DIY investing platform There are already effective vaccines for hepatitis B. But nearly 300 million people suffer long-lasting complications when the body is unable to fend off the virus. Around 900,000 patients die each year from chronic hepatitis B and, even when treated, it can progress to complications including cirrhosis and liver cancer. The pharmaceutical company said initial results from a mid-stage study raised hopes for what it called a 'functional cure'. Chris Corsico, a senior vice president at the company, said yesterday the treatment has the potential to be 'transformative.' GSK, whose chief executive Dame Emma Walmsley has been under attack by Elliott and other shareholders, is poised to spin off its Sensodyne toothpaste and Advil painkillers consumer healthcare business, Haleon, next month.
18/6/2022
21:47
sajad37: 13:00 What investors need to know as GSK and Pfizer spin off Haleon Some analysts see the valuation well short of the £50bn tabled by Unilever, while others reckon GSK will have divested itself of a major "headache" GSK PLC - Sensodyne is one of Haleon's big brands When Haleon PLC is spun off from GSK PLC (LSE:GSK, NYSE:GSK) next month it is expected to be the biggest stock market listing of the past decade. The indicative valuation is £42bn, which begs the question why did the UK drugs giant and its partner Pfizer turn down a £50bn offer from Unilever? This, we’ll never ascertain. The deal affects thousands of private investors, many former GSK employees. So, here’s what you need to know. Timetable July 6 – Approval for the demerger to be given by shareholders. A formality, the event is convenient for international investors as it is being staged at a hotel within the Terminal 5 complex at Heathrow. July 15 – The first part of the separation process begins. This is being done via what’s called a scrip dividend, which means each GSK investor as of the close on the 14th gets shares in the consumer business. GSK will trade on July 15 without the entitlement to shares in Haleon. Its stock is also being consolidated, which means there will be fewer shares in issue. This is to ensure the impact on the share price of the Haleon demerger is mitigated. July 18 – Haleon shares begin trading in London. July 22 – Haleon’s stock will be listed in the US. July 27 – GSK’s second quarter results. This will be the first glimpse of how the slimmed down GSK is performing. November 10 (or sometime around then) - Pfizer’s ‘lock-up’; ends. So, this is a biggie. Normally, significant shareholders such as Pfizer would be asked not to sell equity for at least six months to allow normal trading patterns to be established post-demerger. In some instances, that lock-up period has been known to extend to 18 months or two years. Pfizer, which will own 32% of Haleon, will be released of that obligation in around four months. While the American drug giant has said it will beat an orderly retreat, the market will view the Pfizer stake as a stock overhang situation. This description imagines the shares are a rock and rubble overhang on a cliff wall that has the potential to dislodge then hit and hurt the climbers below. The stock overhang can hit and hurt the share price. From November 10 on (and probably well before), Haleon stock will be under pressure anticipating Pfizer’s exit. What the brokers say Barclays Capital has trawled through 400-odd-page prospectus and distilled its findings into a far less chunky 23-page overview. Two things struck us from the note. The first, was the indicative valuation range, which, based on a price-to-earnings calculation used to assess companies in the consumer staples sector, comes up well short of the £50bn tentatively tabled by Unilever. Barclays reckons Haleon shares, once listed on July 18, could be worth anywhere from 249p to 416p, which adds up to an equity valuation of £23bn-£38bn. This is based on valuations ‘multiplesR17; ranging from 15 to 25 times earnings. The second interesting ‘takeaway̵7; from the note was the bank’s interaction with key shareholders on the issue organic sales growth – a major driver of the company’s valuation. In the note, Barclays said there was “a degree of scepticism” among investors as to whether Haleon could actually hit the 4%-7% top-line target it has set itself. Indeed, it went on to say there was “significant pushback on our 4.7% medium-term growth forecast”. Jefferies, the American bank that has a stellar reputation in the healthcare sector, has assessed the demerger from GSK’s investment perspective. It believes that by spinning out Haleon, whose stock trade is painkillers such as Advil, the UK pharma group has divested itself of a headache (its words not mine). It has based its ‘buy’ recommendation and £21 a share price target on GSK’s own medium-term growth forecasts – an average 6% increase in sales and 12%-14% compound annual growth in per share earnings. “New GSK is underappreciated, as the number-two growth profile in EU large-caps,” Jefferies said in its note. “We accept New GSK pipeline remains a work-in-progress, but catalysts are starting to emerge, and the vaccines franchise just keeps getting better.” One thing to ponder Those who hold GSK currently as income play (it yields 4.7% or thereabouts currently) will see a cut in the combined GSK/Haleon pay-out post-demerger. It is estimated that GSK will distribute around 44p a share in Haleon 11p.
10/6/2022
15:14
tradermichael: A brand that brings science and tech to life Today, GSK is a different company from the GlaxoSmithKline that launched in 2000, and the global context around it has shifted radically. Following the proposed demerger of its consumer healthcare business, GSK will focus purely on biopharma, with a new purpose to unite science, technology and talent to get ahead of disease together. To signal the biggest corporate change at GSK for 20 years, we helped redesign GSK’s brand, to bring to life its purpose, strategy, voice and culture. These updates reflect a GSK focused on driving innovation in the field of biopharma, with new ambitions for patients, shareholders and GSK people. A dynamic, flexible and future-ready system GSK's updated brand identity reflects its new purpose: to unite science, technology and talent to get ahead of disease together. Inspired by the striking imagery found in biosciences, the identity features numerous curved forms that evoke the highly adaptable nature of the human immune system. Housed in a redesigned shape, the ‘signal’, the dynamic new GSK logo always points the way ahead. And the identity system flexes, adapts and moves to engage audiences across the many digital, social and physical environments that brands must embrace to thrive in modern times. A brand identity to get ahead of disease together The new branding showcases the amazing diversity of GSK’s people and partners. It represents talent from across its influential worldwide network, including tens of thousands of GSK people, suppliers and innovative partners. In close collaboration with the team at GSK, we developed a branding system that would work for everyone at GSK. The new branding launched in June 2022, and is being rolled out across the business in the coming months. When a logo requires such an explanation, it does not stand alone and is not self-evident!
01/6/2022
11:12
the grumpy old men: TOP NEWS: GSK files plan for consumer arm demerger with UK regulator Wed, 1st Jun 2022 09:05 Alliance News (Alliance News) - GSK PLC on Wednesday said it has submitted to the UK Financial Conduct Authority its plan for the demerger of its consumer healthcare arm and its listing in London and New York as Haleon. The separation will take the form of a demerger of at least 80% of GSK's current 68% share of the consumer business to GSK shareholders. The remaining 32% of Consumer Healthcare currently is held by US peer Pfizer Inc. Haleon will be listed as ordinary shares in London and as American depositary shares on the New York Stock Exchange. Haleon will provide consumer healthcare products in five categories: Oral Health, Pain Relief, VMS, Respiratory Health, Digestive Health and Other. Oral Health will be its largest component, having contributed 29% of revenue in 2021. GSK will be a pure biopharmaceutical firm, focused on vaccines and specialty medicines. On Tuesday, GSK said it has agreed to pay USD2.1 billion upfront, with potentially a further USD1.2 billion coming, to acquire Boston, Massachusetts-based Affinivax. Affinivax is a clinical-stage biopharmaceutical company focused on developing a novel class of pneumococcal vaccines. GSK on Wednesday said it will carry out a share consolidation following the demerger in order to keep its share price and earnings per share comparable to earlier periods. The company called a general meeting for July 6 at the to approve the plan. The meeting will be held at the Sofitel London Heathrow, Terminal 5 hotel. "The proposed demerger is the most significant corporate change for GSK in the last 20 years, creating two new leading companies, each with clear targets for growth and the ability to positively impact the health and lives of billions of people," GSK said. GSK shares were up 0.2% at 1,736.20 pence early Wednesday in London. By Tom Waite; thomaslwaite@alliancenews.com
26/4/2022
11:53
tradermichael: Last February, the company said sales in 2022, after the consumer unit spin-off, were expected to grow 5% to 7% and adjusted operating profit was forecast to rise 12% to 14%. Wednesday's results should give: 1. An indicator of how close to these projected (good) figures the company is performing 2. Fuller detail on the 'split'. 3. Further infromation on future dividends:GSK expects to declare a 27p per share dividend payable by the current group for the first half of 2022. This comprises 22 pence per share for new GSK and 5 pence per share representing Consumer Healthcare during the first half whilst part of the group. For the second half of 2022, new GSK continues to expect to declare a 22p per share dividend. As previously communicated, new GSK would expect to declare a dividend of 45 pence per share for 2023.
ADVFN Advertorial
Your Recent History
LSE
GSK
Gsk
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220704 15:20:03